Lenox Wealth Advisors’s Orchestra BioMed OBIO Stock Holding History

Lenox Wealth Advisors’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$20K	Hold	2,000	–	–	﹤0.01%	377
2021 Q4	$20K	Buy	+2,000	New	+$19.7K	﹤0.01%	397

Other funds holding OBIO

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Amitell Capital Singapore $109M AUM 50.64% 1-Year Est. Return

Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Lenox Wealth Advisors's OBIO Position: Q1 2022 in Review

Lenox Wealth Advisors held its Orchestra BioMed (OBIO) position steady in Q1 2022 at 2,000 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #377.

Lenox Wealth Advisors first reported a position in OBIO in Q4 2021 and has held it in 2 quarters since. 59 funds tracked by Wall St. Rank hold OBIO as of Q1 2022.

Lenox Wealth Advisors held 2,000 shares of Orchestra BioMed worth $20K as of Q1 2022.
Lenox Wealth Advisors left its Orchestra BioMed share count unchanged in Q1 2022.
Orchestra BioMed made up ﹤0.01% of Lenox Wealth Advisors's portfolio in Q1 2022, its #377 holding.
Lenox Wealth Advisors first reported a position in Orchestra BioMed in Q4 2021 and has held it in 2 quarters since.
59 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2022.

Based on Lenox Wealth Advisors's 13F filing for Q1 2022, filed 14 Apr 2022.